The combined annual revenue of just two GLP-1 peptides, semaglutide and tirzepatide, is projected to exceed $55 billion. This figure nearly rivals the revenue of the entire AI large language model industry, demonstrating the massive, often underestimated, economic scale of the market for effective metabolic health solutions.

After reporting strong earnings and a positive forecast for its GLP-1 drugs, Eli Lilly's market capitalization increased by nearly $100 billion in a single trading day. This staggering gain, equivalent to the entire value of another large pharma company, highlights the immense investor confidence in its competitive position.

While AI dominates headlines, GLP-1s offer more immediate and tangible improvements to human health and quality of life. The market impact of solving pervasive health crises like obesity, addiction, and heart disease may ultimately dwarf the current perceived value of AI.

Scott Galloway argues that GLP-1 drugs (like Ozempic) will have a greater impact on people's lives and ultimately create more shareholder value than artificial intelligence. When asked, individuals who use both would likely give up AI before their GLP-1 medication, highlighting its profound personal impact.

Scott Galloway and Eli Lilly's CEO David Ricks both contend that GLP-1 technology is currently underhyped, while AI is overhyped. They argue GLP-1s will ultimately have a more profound and transformative impact on society and health than artificial intelligence.

While AI dominates headlines, GLP-1 drugs could have a more profound and immediate impact on society. They address the core mechanism of desire ("wanting less"), with applications for obesity, addiction, and compulsive behaviors that could fundamentally reshape public health and daily life.

The massive success of GLP-1s is not just about a $100B drug class. It's the first commercial proof that consumers are actively choosing preventative medicine, paving the way for a broader, trillion-dollar revolution in public health spending and behavior.

Scott Galloway argues GLP-1 drugs (like Ozempic) will have a greater societal impact than AI. By tackling obesity, they could halve U.S. healthcare costs, help solve the deficit, and even curb addictions, making them a profoundly transformative technology.

The long-held belief that solving obesity would create immense wealth is now validated by Eli Lilly's $1T market cap, driven by its GLP-1 weight-loss drugs. This marks a significant shift, as the trillion-dollar club was previously dominated by tech and oil companies.